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WEARABLE DEVICES: MONITORING THE
FUTURE?
Wearable devices are becoming increasingly utilized in our con-
temporary world, and the Apple Watch is a popular tool for
monitoring the heart rate and more recently, heart rhythm. The
Apple Watch Series 4 was the first one granted clearance by the
Food and Drug Administration (FDA), allowing rhythm detection
and identification of Atrial Fibrillation (AF), on 11 September
2018; outlying however that the definitive diagnosis should not
be made before a doctor confirms the validity of the possible
alarm signal transmitted by the watch [1]. Nonetheless, Apple
watches have been used to inform patients about other rhythm
abnormalities as well. In this issue of Oxford Medical Case
Reports, Goldstein and Wells present the case of a previously
asymptomatic 56-year-old man diagnosed with Atrial Flutter
after he noticed a high rate on his watch, which coincided with
palpitations. He contacted the medical services 4 days later and
an electrocardiogram (ECG) confirmed Atrial Flutter with a 2:1
AV block (Fig. 1). He proceeded to receive anticoagulation and
a transoesophageal echocardiogram-guided electrical cardiover-
sion [2]. In this case of an individual with a high thromboembolic
risk score, it was clear that the AppleWatch had an instrumental
role in identifying the abnormal rhythm and subsequent con-
firmation of the Atrial Flutter thus allowing further appropriate
medical intervention and pharmacotherapy.
However, concerns have been raised about the accuracy of the
watch with regards to rhythm abnormality detection, the need
for perhaps unnecessary downstream testing in some individ-
uals and ultimately whether it will benefit patients or simply
increase the level of anxiety in those noticing abnormal heart
rates or receiving notifications for abnormal findings. Only large
population-based registries will allow us to place the exact role
of the Apple Watch.
The Apple Watch is a commercially available device, which
can be found in stores and online, thus being more commonly
used by healthy individuals. It is effective for measuring heart
rate [3], andmoreover, as it can detect abnormal cardiac rhythm,
it may prove helpful to people who occasionally have symptoms
such as palpitations. Newer versions of the device can record
the ECG for subsequent reading by a physician, but this func-
tion was not available in the country where the patient was
present [4].
To support the potentially beneficial role of the Apple Watch,
the large Apple Heart observational study of 419 297 participants
using an Apple Watch over a period of 8 months has been
recently published, the ‘Large-Scale Assessment of a Smart-
watch to Identify Atrial Fibrillation’. This showed that detection
of possible AF for more than 30 seconds was seen in 0.5% of
the participants (who were generally younger) but for those over
the age of 65, this rose to 3.2%. When the device recording was
compared to an ECGpatch, the positive predictive valuewas 0.84,
which is very encouraging for potential clinical use [5].
However, there are certain limitations, which need to be
considered. Firstly, there is a concern over the possible over-
diagnosis of AF and the unnecessary anxiety that this could
bring. Smart watches demonstrate high sensitivity but generally
speaking, lower specificity, although with improving technology
this is likely to also increase. Therefore, episodes of an otherwise
benign dysrhythmia,may bemisinterpreted as abnormal, result-
ing in patient stress, downward testing and even unnecessary
anticoagulation treatment [6].
Linked with this is the fact that such wearable devices are
utilized mainly by young healthy individuals who have a very
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Figure 1: ECG undertaken following the Apple watch notifications demonstrating atrial flutter.
low risk of AF, and therefore, the overall risk of a false positive
notification of AF will be higher than the elderly population,
who might be less likely to use an Apple Watch [7, 8]. Even then,
anticoagulation is unlikely to be indicated or beneficial in young;
otherwise healthy individuals with very low thromboembolic
risk.
Furthermore, another concern stems from theway the device
operates. The watch, which is placed on the wrist, has an optical
sensor detecting pulse waveform to passively measure heart
rate [9]. Then, using an algorithm, each pulse peak is translated
into an R wave in the ECG. Detection of this pulse irregularity is
used to identify atrial fibrillation. It is evident that potential skin
sensitivities could possibly interrupt this procedure and lead to
inaccurate measurements [10].
However, despite its any possible disadvantages, the Apple
Watch is here to stay. It is likely to help patients identify
AF and also any other potential rhythm abnormalities in
the future, but at the risk of necessitating significant down-
ward testing in healthy individuals. In addition, many more
companies are expected to produce similar wearables, thus
leading to more people having access to home monitoring
and then referring to physicians for further investigations [11].
Given that these devices can be easily purchased by healthy
individuals, as physicians we need to expect and prepare for
reviewing patients following Smart Watch notifications as
they will become a more common feature of the daily clinical
practice.
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